BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Cipla Q2 Results FY24-25 Highlights: Cons Revenue at ₹7,051 Cr Up 9%, PAT at ₹1,303 Cr Surged 17% YoY

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Cipla Limited has reported consolidated Q2 results for FY24-25, showcasing a steady rise in financial performance. The company recorded a revenue of ₹7,051 Cr, an 8.6% YoY increase, and a PAT of ₹1,303 Cr, marking a 16.9% growth. This growth is attributed to strong sales across segments, particularly in India and North America.

Key Highlights/Quick Insights

  • Total Revenue: ₹7,051 Cr (8.6% YoY growth)
  • EBITDA: ₹1,886 Cr, with an 11.6% YoY increase
  • PAT: ₹1,303 Cr, reflecting a 16.9% increase
  • EBITDA Margin: 26.7%, a 70 basis points rise
  • PAT Margin: 18.5%, an improvement of 130 basis points

CIPLA LTD

Trade

1525.6-24.50 (-1.58 %)

Updated - 02 May 2025
1552.50day high
DAY HIGH
1513.50day low
DAY LOW
2020145
VOLUME (BSE)

Quarterly Performance – Cipla Q2 Results FY24-25

Cipla’s quarterly performance has been buoyed by growth in domestic and North American markets, with substantial improvements in the chronic segment

Other Income:Expenses:

Metric

Q2 FY25

Q2 FY24

YoY % Change

Revenue from Operations

₹7,051 Cr

₹6,678 Cr

8.60%

EBITDA

₹1,886 Cr

₹1,689 Cr

11.60%

PAT

₹1,303 Cr

₹1,155 Cr

16.90%

EBITDA Margin

26.70%

26.00%

+70 bps

PAT Margin

18.50%

17.20%

+130 bps

Employee Benefits Expense

₹1,208 Cr

₹1,091 Cr

9%

Depreciation & Amortization

₹272 Cr

₹290 Cr

-6%

Segment Highlights

One India:North America:Africa and Emerging Markets:

Sector Expectations for Cipla 2Q Results FY24-25

Cipla's results align with sector expectations, especially in chronic therapies like respiratory and cardiac, where growth continues despite industry challenges. The management's strategic focus on high-growth markets has been instrumental in surpassing sector benchmarks.

Management Commentary

Cipla’s management expressed satisfaction with the quarter’s performance, attributing growth to strategic launches and robust demand in core therapeutic areas. The leadership emphasized continued investment in R&D and expansion across high-growth segments.

Check out Cipla's past performances in previous quarters and financial years. 

Conclusion

Cipla’s Q2 FY24-25 results underscore its growth trajectory in both domestic and international markets. With a strong pipeline, particularly in the North American generic segment, Cipla remains committed to sustainable growth. The company's strategic focus on key therapies and segments continues to drive value for stakeholders. 

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9.5 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4400+ Cr MTF Book

icon-with-text